267647-89-2

Usage

Uses

Used in Pharmaceutical Industry:
(3-methoxy-4-oxazol-5-yl-phenyl)-thiourea is used as a potential pharmaceutical candidate for various applications due to its unique structural features and potential biological activities, such as anticancer, antimicrobial, and anti-inflammatory properties.
Used in Research and Development:
(3-methoxy-4-oxazol-5-yl-phenyl)-thiourea is used as a subject of research and studies to fully understand its properties and potential uses in various fields such as medicine and agriculture. Further research is needed to explore its potential applications and optimize its efficacy.

Upstream product

• 213262-06-7 3-Methoxy-4-(5-oxazolyl)phenyl isothiocyanate 
• 198821-79-3 3-methoxy-4-(1,3-oxazol-5-yl)aniline 
• 532-55-8 Benzoyl isothiocyanate 

Downstream Products

• 1172637-80-7 (3-methoxy-4-oxazol-5-yl-phenyl)-(4-phenyl-4,5,6,7-tetrahydro-benzothiazol-2-yl)-amine 

Relevant academic research and scientific papers

MODULATORS FOR AMYLOID BETA

The invention relates to compounds of formula wherein R1, R2, R3, R4, X and Y are as defined herein and to pharmaceutically active acid addition salts thereof. The compounds can be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

A survey of cyclic replacements for the central diamide moiety of inhibitors of inosine monophosphate dehydrogenase

A series of heterocyclic replacements for the central diamide moiety of 1, a potent small molecule inhibitor of inosine monophosphate dehydrogenase (IMPDH) were explored. The synthesis and the structure-activity relationships (SARs), derived from in vitro

Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme

The present invention discloses the identification of the novel inhibitors of IMPDH (inosine-5′-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH mediated diseases, such as transplant rejection and autoimmune diseases.